Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Kidney Cancer and Thyroid Neoplasms, 44673 [05-15345]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 148 / Wednesday, August 3, 2005 / Notices
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 19, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–15343 Filed 8–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: Therapeutics for the
Treatment of Kidney Cancer and
Thyroid Neoplasms
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), announces that the
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to practice the
inventions embodied in
1. E–199–2002/0–US–01, ‘‘Treatment
Method and Therapeutic Agent of
Kidney Cancer’’, by Susan Bates, and
Yoshinori Naoe, Pat. Application No.
60/369,868 (filing date April 5, 2002);
2. E–199–2002/0–PCT–02, ‘‘Treatment
Method and Therapeutic Agent of
Kidney Cancer’’, by Susan Bates, and
Yoshinori Naoe, Pat. Application No.
PCT/US03/03823 (filing date March 27,
2003);
3. E–199–2002/0–US–04,
‘‘Depsipeptide for Therapy of Kidney
Cancer’’, by Susan Bates, and Yoshinori
Naoe, Pat. Application No. 10/508,958
(filing date October 5, 2004);
4. E–199–2002/0–JP–08,
‘‘Depsipeptide for Therapy of Kidney
Cancer’’, by Susan Bates, and Yoshinori
Naoe, Pat. Application No. 20003581847
(filing date October 5, 2004);
5. E–199–2002/0–EP–05,
‘‘Depsipeptide for Therapy of Kidney
Cancer’’, by Susan Bates, and Yoshinori
Naoe, Pat Application No.037155033–
2107 (filing date October 8, 2004);
6. E–286–2000/0–US–01, ‘‘Histone
Deacetylase Inhibitors in Diagnosis and
Treatment of Thyroid Neoplasms’’, by
Tito Fojo and Susan Bates, Pat.
Application No. 60/260,733 (filing date
January 10, 2001);
VerDate jul<14>2003
15:22 Aug 02, 2005
Jkt 205001
7. E–286–2000/0–US–02, ‘‘Histone
Deacetylase Inhibitors in Diagnosis and
Treatment of Thyroid Neoplasms’’, by
Tito Fojo and Susan Bates, Pat.
Application No. PCT/US02/0714 (filing
date January 9, 2001);
8. E–286–2000/0–EP–03, ‘‘Histone
Deacetylase Inhibitors in Diagnosis and
Treatment of Thyroid Neoplasms’’, by
Tito Fojo and Susan Bates, Pat.
Application No. 02718823.4 (filing date
January 9, 2001);
9. E–286–2000/0–AU–04, ‘‘Histone
Deacetylase Inhibitors in Diagnosis and
Treatment of Thyroid Neoplasms’’, by
Tito Fojo and Susan Bates, Pat.
Application No. 2002249938 (filing date
January 9, 2001);
10. E–286–2000/0–CA–04, ‘‘Histone
Deacetylase Inhibitors in Diagnosis and
Treatment of Thyroid Neoplasms’’, by
Tito Fojo and Susan Bates, Pat.
Application No. 2434269 (filing date
January 9, 2001);
11. E–286–2000/0–US–07, ‘‘Histone
Deacetylase Inhibitors in Diagnosis and
Treatment of Thyroid Neoplasms’’, by
Tito Fojo and Susan Bates, Pat.
Application No. 10/250,320 (filing date
June 26, 2003);
12. E–286–2000/0–JP–05, ‘‘Histone
Deacetylase Inhibitors in Diagnosis and
Treatment of Thyroid Neoplasms’’, by
Tito Fojo and Susan Bates, Pat.
Application No. 2002–556736 (filing
date July 10, 2003)
to Gloucester Pharmaceticals, having a
place of business in Cambridge, MA.
The patent rights in these inventions
have been assigned to the United States
of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to
therapeutics for the treatment of Kidney
Cancer and Thyroid Neoplasms.
DATES: Only written comments and/or
license applications which are received
by the National Institutes of Health on
or before October 3, 2005 will be
considered.
Requests for copies of the
patent and/or patent applications,
inquiries, comments and other materials
relating to the contemplated exclusive
license should be directed to: John
Stansberrry, Ph.D., Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–5236; Facsimile:
(301) 402–0220; E-mail:
stansbej@mail.nih.gov.
ADDRESSES:
The
inventions describe methods of treating
kidney cancer and thyroid neoplasms
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00121
Fmt 4703
Sfmt 4703
44673
with FK228, which is a histone
deacetylase (HDAC) inhibitor. FK228 is
currently in Phase II clinical trials, and
has been shown to inhibit histone
deacetylation, a process instrumental in
the regulation of gene expression.
FK228 modulates cell cycle arrest and
can promote differentiation and
apoptosis. To date, FK228 has been
administered to more than 300 patients
and has shown promising clinical
activity in Phase II trials for patients
with cutaneous T-cell lymphoma
(CTCL). Clinical responses have also
been observed in Phase II studies in
peripheral T-cell lymphoma, renal cell
carcinoma (RCC) and hormone
refractory prostate cancer (HRPC).
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 26, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–15345 Filed 8–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: Anti-Cancer Vaccines
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), announces that the
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to practice the
inventions embodied in U.S. Patent
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 70, Number 148 (Wednesday, August 3, 2005)]
[Notices]
[Page 44673]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15345]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive License: Therapeutics for the
Treatment of Kidney Cancer and Thyroid Neoplasms
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), announces that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive license to practice the inventions embodied in
1. E-199-2002/0-US-01, ``Treatment Method and Therapeutic Agent of
Kidney Cancer'', by Susan Bates, and Yoshinori Naoe, Pat. Application
No. 60/369,868 (filing date April 5, 2002);
2. E-199-2002/0-PCT-02, ``Treatment Method and Therapeutic Agent of
Kidney Cancer'', by Susan Bates, and Yoshinori Naoe, Pat. Application
No. PCT/US03/03823 (filing date March 27, 2003);
3. E-199-2002/0-US-04, ``Depsipeptide for Therapy of Kidney
Cancer'', by Susan Bates, and Yoshinori Naoe, Pat. Application No. 10/
508,958 (filing date October 5, 2004);
4. E-199-2002/0-JP-08, ``Depsipeptide for Therapy of Kidney
Cancer'', by Susan Bates, and Yoshinori Naoe, Pat. Application No.
20003581847 (filing date October 5, 2004);
5. E-199-2002/0-EP-05, ``Depsipeptide for Therapy of Kidney
Cancer'', by Susan Bates, and Yoshinori Naoe, Pat Application
No.037155033-2107 (filing date October 8, 2004);
6. E-286-2000/0-US-01, ``Histone Deacetylase Inhibitors in
Diagnosis and Treatment of Thyroid Neoplasms'', by Tito Fojo and Susan
Bates, Pat. Application No. 60/260,733 (filing date January 10, 2001);
7. E-286-2000/0-US-02, ``Histone Deacetylase Inhibitors in
Diagnosis and Treatment of Thyroid Neoplasms'', by Tito Fojo and Susan
Bates, Pat. Application No. PCT/US02/0714 (filing date January 9,
2001);
8. E-286-2000/0-EP-03, ``Histone Deacetylase Inhibitors in
Diagnosis and Treatment of Thyroid Neoplasms'', by Tito Fojo and Susan
Bates, Pat. Application No. 02718823.4 (filing date January 9, 2001);
9. E-286-2000/0-AU-04, ``Histone Deacetylase Inhibitors in
Diagnosis and Treatment of Thyroid Neoplasms'', by Tito Fojo and Susan
Bates, Pat. Application No. 2002249938 (filing date January 9, 2001);
10. E-286-2000/0-CA-04, ``Histone Deacetylase Inhibitors in
Diagnosis and Treatment of Thyroid Neoplasms'', by Tito Fojo and Susan
Bates, Pat. Application No. 2434269 (filing date January 9, 2001);
11. E-286-2000/0-US-07, ``Histone Deacetylase Inhibitors in
Diagnosis and Treatment of Thyroid Neoplasms'', by Tito Fojo and Susan
Bates, Pat. Application No. 10/250,320 (filing date June 26, 2003);
12. E-286-2000/0-JP-05, ``Histone Deacetylase Inhibitors in
Diagnosis and Treatment of Thyroid Neoplasms'', by Tito Fojo and Susan
Bates, Pat. Application No. 2002-556736 (filing date July 10, 2003)
to Gloucester Pharmaceticals, having a place of business in Cambridge,
MA. The patent rights in these inventions have been assigned to the
United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to therapeutics for the treatment of
Kidney Cancer and Thyroid Neoplasms.
DATES: Only written comments and/or license applications which are
received by the National Institutes of Health on or before October 3,
2005 will be considered.
ADDRESSES: Requests for copies of the patent and/or patent
applications, inquiries, comments and other materials relating to the
contemplated exclusive license should be directed to: John Stansberrry,
Ph.D., Technology Licensing Specialist, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Telephone: (301) 435-5236; Facsimile: (301)
402-0220; E-mail: stansbej@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The inventions describe methods of treating
kidney cancer and thyroid neoplasms with FK228, which is a histone
deacetylase (HDAC) inhibitor. FK228 is currently in Phase II clinical
trials, and has been shown to inhibit histone deacetylation, a process
instrumental in the regulation of gene expression. FK228 modulates cell
cycle arrest and can promote differentiation and apoptosis. To date,
FK228 has been administered to more than 300 patients and has shown
promising clinical activity in Phase II trials for patients with
cutaneous T-cell lymphoma (CTCL). Clinical responses have also been
observed in Phase II studies in peripheral T-cell lymphoma, renal cell
carcinoma (RCC) and hormone refractory prostate cancer (HRPC).
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, the NIH receives
written evidence and argument that establish that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 26, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-15345 Filed 8-2-05; 8:45 am]
BILLING CODE 4140-01-P
